EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Safety of antithrombotic therapy in hereditary hemorrhagic telangiectasia: results from a prospective cohort study

Luigi Di Martino, Fabiana Agostini, Daniela Feliciani, Barbara Funaro, Annarita Barberio, Rosa Talerico, Antonio Gasbarrini, Roberto Pola, Eleonora Gaetani

Research and Practice in Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.rpth.2026.106943 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026. Verfasst von Luigi Di Martino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hereditary Hemorrhagic Telangiectasia Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Fibrinolytic Agents, Anticoagulants, Platelet Aggregation Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder characterized by a predominant bleeding phenotype. However, patients are also at risk of thrombotic events and may require antithrombotic therapy (AT), for which safety data remain limited.

Objectives

To prospectively evaluate the safety of AT in patients with HHT using standardized longitudinal assessment of bleeding outcomes.

Methods

We conducted a prospective observational study at a tertiary HHT referral center. Patients with a definite diagnosis of HHT and a new indication for antiplatelet or anticoagulant therapy were enrolled. The primary outcome was the incidence of hemorrhagic events, classified according to the International Society on Thrombosis and Haemostasis criteria. Secondary outcomes included worsening of epistaxis assessed by the Epistaxis Severity Score, changes in hemoglobin levels, and transfusion requirements.

Results

A total of 33 patients (mean age 65.8 ± 12.9 years; 69.7% male) were included, for a total of 41 AT courses. During a mean follow-up of 21.1 ± 19.2 months, 2 major bleeding events (4.9%) occurred, both during anticoagulant therapy. Three clinically relevant nonmajor bleeds and one minor bleed were recorded. Worsening of epistaxis occurred in 24.4% of treatment courses, but mean Epistaxis Severity Score values did not differ from baseline. Hemoglobin levels and transfusion requirements were not significantly affected.

Conclusions

In this prospective cohort, AT was associated with an acceptable safety profile in selected patients with HHT managed in a multidisciplinary setting. These findings strengthen the currently limited prospective evidence supporting individualized antithrombotic management in HHT, although larger multicenter prospective studies remain warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Telangiectasia, Hereditary HemorrhagicFibrinolytic AgentsAnticoagulantsPlatelet Aggregation InhibitorsHumansMaleFemaleProspective StudiesAgedEpistaxisMiddle AgedTreatment OutcomeBlood Transfusion

Stichwörter der Autor:innen

antithrombotic therapybleeding riskepistaxishereditary hemorrhagic telangiectasiaprospective cohort studyvenous thromboembolism

Substanzen

Fibrinolytic AgentsAnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Hereditary Hemorrhagic Telangiectasia Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Unità Operativa Complessa di Medicina Interna, Ospedale Cristo Re, Rome, Italy.
  • Unità Operativa Complessa of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Percorso Trombosi, Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.

Zitieren

APA

Di Martino, L., Agostini, F., Feliciani, D., Funaro, B., Barberio, A., Talerico, R., Gasbarrini, A., Pola, R., & Gaetani, E. (2026). Safety of antithrombotic therapy in hereditary hemorrhagic telangiectasia: results from a prospective cohort study. Research and Practice in Thrombosis and Haemostasis. https://doi.org/10.1016/j.rpth.2026.106943

Vancouver

Di Martino L, Agostini F, Feliciani D, Funaro B, Barberio A, Talerico R, et al. Safety of antithrombotic therapy in hereditary hemorrhagic telangiectasia: results from a prospective cohort study. Research and Practice in Thrombosis and Haemostasis. 2026. doi:10.1016/j.rpth.2026.106943

BibTeX
@article{DiMartino2026,
  author = {Di Martino, Luigi and Agostini, Fabiana and Feliciani, Daniela and Funaro, Barbara and Barberio, Annarita and Talerico, Rosa and Gasbarrini, Antonio and Pola, Roberto and Gaetani, Eleonora},
  title = {Safety of antithrombotic therapy in hereditary hemorrhagic telangiectasia: results from a prospective cohort study},
  journal = {Research and Practice in Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.rpth.2026.106943}
}
Kostenlos starten →